Maintenance fees coming due
12 maintenance fees come due in the 12 months from Nov 16, 2026, the next on Feb 15, 2027. Unpaid by Aug 16, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5
and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the
six month grace period that follows.
| Patent | Title | Holder | Status | Fee due | Lapses if unpaid | Expires | Confidence |
|---|---|---|---|---|---|---|---|
| US 11,723,905 | Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile In force Fee due Feb 15, 2027 Lapses if unpaid Aug 16, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Feb 15, 2027 | Aug 16, 2027 | High confidence | |
| US 11,738,018 | Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1) In force Fee due Feb 28, 2027 Lapses if unpaid Aug 30, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Feb 28, 2027 | Aug 30, 2027 | High confidence | |
| US 10,399,980 | Purinones as Ubiquitin-Specific Protease 1 Inhibitors In force Fee due Mar 3, 2027 Lapses if unpaid Sep 3, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Mar 3, 2027 | Sep 3, 2027 | High confidence | |
| US 10,414,752 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force Fee due Mar 17, 2027 Lapses if unpaid Sep 17, 2027 · Low confidence | Forma Therapeutics, Inc. | In force | Mar 17, 2027 | Sep 17, 2027 | Low confidence | |
| US 11,787,803 | Tetrahydro-Imidazo Quinoline Compositions as CBP/P300 Inhibitors In force Fee due Apr 17, 2027 Lapses if unpaid Oct 18, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Apr 17, 2027 | Oct 18, 2027 | High confidence | |
| US 11,795,168 | Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP) In force Fee due Apr 24, 2027 Lapses if unpaid Oct 25, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Apr 24, 2027 | Oct 25, 2027 | High confidence | |
| US 11,801,243 | Bromodomain Inhibitors for Androgen Receptor-Driven Cancers In force Fee due Apr 30, 2027 Lapses if unpaid Nov 1, 2027 · High confidence | Forma Therapeutics, Inc. | In force | Apr 30, 2027 | Nov 1, 2027 | High confidence | |
| US 11,814,386 | Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors In force Fee due May 14, 2027 Lapses if unpaid Nov 15, 2027 · High confidence | Forma Therapeutics, Inc. | In force | May 14, 2027 | Nov 15, 2027 | High confidence | |
| US 10,532,047 | Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile In force Fee due Jul 14, 2027 Lapses if unpaid Jan 14, 2028 · High confidence | Forma Therapeutics, Inc. | In force | Jul 14, 2027 | Jan 14, 2028 | High confidence | |
| US 10,550,098 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force Fee due Aug 4, 2027 Lapses if unpaid Feb 4, 2028 · Low confidence | Forma Therapeutics, Inc. | In force | Aug 4, 2027 | Feb 4, 2028 | Low confidence | |
| 2 more maintenance fees coming due in the 12 months from Nov 16, 2026 · Pro | |||||||
10 of 12 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.